AnaptysBio Inc

ANABNASDAQ · USD
45.61USD0.00 (-0.27%)
349

AnaptysBio Inc (ANAB) Covered Calls

AnaptysBio Inc trades in the Biotechnology industry with an IV Rank of 90.87%, high versus the past year. ANAB's highest covered call setup is the $50.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 9.34% out of the money with 4 days to expiration, a 9.77% return until expiration, and a 891.95% theoretical annualized return. Across the setups shown, annualized returns run from 128.61% to 891.95% at strikes between $50.00 and $80.00, with 4 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running ANAB covered calls helps you generate income from AnaptysBio Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ANAB covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ANAB stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANAB covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ANAB covered call is worth writing.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

2026-11-20450.009.340.203.50447.009.77891.95-0.44+0.35133.30
2027-02-199580.0074.940.104.903437.0075.16288.77-0.22+0.22494.80
2027-02-199575.0064.010.204.902947.0064.44247.60-0.44+0.2464.70
2026-12-183255.0020.270.104.90937.0020.49233.71-0.22+0.32164.80
2027-02-199570.0053.070.104.902437.0053.29204.75-0.22+0.257024.80
2027-02-199565.0042.140.704.901997.0043.67167.78-1.53+0.28224.20
2027-05-2118680.0074.940.504.903477.0076.03149.21-1.09+0.2404.40
2026-12-183250.009.341.656.00592.0012.95147.66-3.61+0.44264.35
2027-02-199560.0031.201.405.501567.0034.27131.65-3.06+0.3474.10
2027-05-2118675.0064.010.704.902997.0065.54128.61-1.53+0.25164.20

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank90.87% High
  • Market cap (M$)1,356
  • 52 weeks high-36.97%
  • 52 weeks low106.75%
  • Analyst recommendationStrong Buy
    1.14
  • Target price$79.71
    74.76% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-12
  • P/E7.56
  • Future P/E—
  • EPS (ttm)6.04
  • EPS growth next 5 years—

As of Nov 16, 2026